CRISPR gene editing is no longer science fiction — it’s an FDA-approved treatment transforming lives with sickle cell disease and beta-thalassemia. In this episode of the DoctorPodcasts, host Dr. Robert Cykiert sits down with Dr. Akshay Sharma, Associate Member at St. Jude Children’s Research Hospital and a leading expert in gene therapy and bone marrow transplantation. Dr. Sharma was involved in the clinical trials that led to the approval of Casgevy. Discover how a single DNA edit can raise fetal hemoglobin, stop painful crises, and potentially free patients from lifelong transfusions and organ damage. Learn the real differences between gene therapy and traditional bone marrow transplant, the full treatment timeline, risks (including busulfan chemotherapy), expansion to younger patients, and how AI could accelerate the next generation of cures. This is one of the most important medical breakthroughs of our time. Timeline / Chapters: 0:00 – Introduction & Guest Welcome 2:16 – What is Sickle Cell Disease? The Genetic Defect Explained 5:37 – Inheritance Pattern & How Many People Are Affected 7:04 – Sickle Cell Trait vs. Disease 7:50 – Historical Treatments: Supportive Care, Hydroxyurea & More 12:23 – Bone Marrow Transplant History (First Success at St. Jude in 1983) 13:27 – What is Beta-Thalassemia? 15:40 – How Casgevy Differs from Transfusions & Transplants 20:25 – How CRISPR Gene Editing Works (The Molecular Scissors) 25:48 – Clinical Trials, FDA Approval (Dec 2023) & Age Expansion 30:36 – Treating Young Children: Long-Term Outlook 34:54 – Full Treatment Timeline (9–12 Months) 37:12 – Role of AI in Future Gene Therapies 39:35 – Closing Thoughts #Casgevy, #CRISPR, #sickle #thalassemia, #gene #hemoglobin, #bonemarrowtransplant, , , , #Vertex #CRISPR #DNA #Doctorpodcasts #Cykiert Subscribe for more expert interviews on breakthrough medical treatments. Like, share, and comment with your questions!